KR20140041381A - 로팔러러스 정셔스 전갈 독으로부터의 펩티드 및 약리학적 조성물 - Google Patents
로팔러러스 정셔스 전갈 독으로부터의 펩티드 및 약리학적 조성물 Download PDFInfo
- Publication number
- KR20140041381A KR20140041381A KR1020137010868A KR20137010868A KR20140041381A KR 20140041381 A KR20140041381 A KR 20140041381A KR 1020137010868 A KR1020137010868 A KR 1020137010868A KR 20137010868 A KR20137010868 A KR 20137010868A KR 20140041381 A KR20140041381 A KR 20140041381A
- Authority
- KR
- South Korea
- Prior art keywords
- peptide
- rjlb
- scorpion
- venom
- poison
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 42
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 6
- 241001050861 Rhopalurus junceus Species 0.000 title claims description 4
- 239000002435 venom Substances 0.000 title description 29
- 231100000611 venom Toxicity 0.000 title description 29
- 210000001048 venom Anatomy 0.000 title description 29
- 239000002795 scorpion venom Substances 0.000 claims abstract description 26
- 239000000203 mixture Substances 0.000 claims abstract description 25
- 231100000614 poison Toxicity 0.000 claims description 39
- 239000002574 poison Substances 0.000 claims description 39
- 241000239226 Scorpiones Species 0.000 claims description 36
- 210000004881 tumor cell Anatomy 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 16
- 230000009471 action Effects 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000012153 distilled water Substances 0.000 claims description 7
- 230000001472 cytotoxic effect Effects 0.000 claims description 5
- 231100000433 cytotoxic Toxicity 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 230000000699 topical effect Effects 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 239000008196 pharmacological composition Substances 0.000 claims 3
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 34
- 230000004083 survival effect Effects 0.000 abstract description 20
- 102000004169 proteins and genes Human genes 0.000 abstract description 19
- 108090000623 proteins and genes Proteins 0.000 abstract description 19
- 201000011510 cancer Diseases 0.000 abstract description 18
- 230000000202 analgesic effect Effects 0.000 abstract description 13
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 11
- 239000003814 drug Substances 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 7
- 210000004698 lymphocyte Anatomy 0.000 abstract description 4
- 150000001413 amino acids Chemical class 0.000 abstract description 3
- 230000003217 anti-cancerogenic effect Effects 0.000 abstract description 3
- 150000001720 carbohydrates Chemical class 0.000 abstract description 2
- 235000014633 carbohydrates Nutrition 0.000 abstract description 2
- 150000003839 salts Chemical class 0.000 abstract description 2
- 150000002500 ions Chemical class 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 33
- 230000000694 effects Effects 0.000 description 30
- 239000003053 toxin Substances 0.000 description 23
- 231100000765 toxin Toxicity 0.000 description 23
- 108700012359 toxins Proteins 0.000 description 23
- 238000011282 treatment Methods 0.000 description 22
- 241000700159 Rattus Species 0.000 description 21
- 230000004614 tumor growth Effects 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 17
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 238000011156 evaluation Methods 0.000 description 13
- 230000005764 inhibitory process Effects 0.000 description 11
- 230000000366 juvenile effect Effects 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 206010010904 Convulsion Diseases 0.000 description 9
- 208000032612 Glial tumor Diseases 0.000 description 9
- 206010018338 Glioma Diseases 0.000 description 9
- 210000004072 lung Anatomy 0.000 description 9
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 8
- 206010018691 Granuloma Diseases 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 210000004303 peritoneum Anatomy 0.000 description 8
- 239000013641 positive control Substances 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 206010006187 Breast cancer Diseases 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 238000010171 animal model Methods 0.000 description 7
- 230000000259 anti-tumor effect Effects 0.000 description 7
- 229940117173 croton oil Drugs 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- 230000036407 pain Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 229960001138 acetylsalicylic acid Drugs 0.000 description 6
- 201000008274 breast adenocarcinoma Diseases 0.000 description 6
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 5
- 241001529936 Murinae Species 0.000 description 5
- 230000003187 abdominal effect Effects 0.000 description 5
- 230000030833 cell death Effects 0.000 description 5
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 5
- 229960003957 dexamethasone Drugs 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 238000007912 intraperitoneal administration Methods 0.000 description 5
- 238000003819 low-pressure liquid chromatography Methods 0.000 description 5
- 201000005202 lung cancer Diseases 0.000 description 5
- 208000020816 lung neoplasm Diseases 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 101710164760 Chlorotoxin Proteins 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- QPAKKWCQMHUHNI-GQIQPHNSSA-N chlorotoxin Chemical compound C([C@H]1C(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]4CSSC[C@@H](C(N[C@@H](CCSC)C(=O)N5CCC[C@H]5C(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)CNC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC2=O)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC4=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N3)=O)NC(=O)[C@@H](N)CCSC)C1=CC=C(O)C=C1 QPAKKWCQMHUHNI-GQIQPHNSSA-N 0.000 description 4
- 229960005534 chlorotoxin Drugs 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108010087765 Antipain Proteins 0.000 description 3
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 206010061309 Neoplasm progression Diseases 0.000 description 3
- 230000036592 analgesia Effects 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 description 3
- 235000012730 carminic acid Nutrition 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 229960004126 codeine Drugs 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 210000005069 ears Anatomy 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000011141 high resolution liquid chromatography Methods 0.000 description 3
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 210000003097 mucus Anatomy 0.000 description 3
- FRZJZRVZZNTMAW-UHFFFAOYSA-N n,n-diethyl-3-(hydroxymethyl)benzamide Chemical compound CCN(CC)C(=O)C1=CC=CC(CO)=C1 FRZJZRVZZNTMAW-UHFFFAOYSA-N 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical group C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 3
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000005751 tumor progression Effects 0.000 description 3
- 241000238421 Arthropoda Species 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 241000168486 Causus Species 0.000 description 2
- 108010062745 Chloride Channels Proteins 0.000 description 2
- 102000011045 Chloride Channels Human genes 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 230000005778 DNA damage Effects 0.000 description 2
- 231100000277 DNA damage Toxicity 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 241001481692 Mesobuthus martensii Species 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- BPLKXBNWXRMHRE-UHFFFAOYSA-N copper;1,10-phenanthroline Chemical compound [Cu].C1=CN=C2C3=NC=CC=C3C=CC2=C1 BPLKXBNWXRMHRE-UHFFFAOYSA-N 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000002270 exclusion chromatography Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 230000001632 homeopathic effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 230000009191 jumping Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- ZPEZUAAEBBHXBT-WCCKRBBISA-N (2s)-2-amino-3-methylbutanoic acid;2-amino-3-methylbutanoic acid Chemical compound CC(C)C(N)C(O)=O.CC(C)[C@H](N)C(O)=O ZPEZUAAEBBHXBT-WCCKRBBISA-N 0.000 description 1
- XMTQQYYKAHVGBJ-UHFFFAOYSA-N 3-(3,4-DICHLOROPHENYL)-1,1-DIMETHYLUREA Chemical compound CN(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XMTQQYYKAHVGBJ-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 241000239225 Buthidae Species 0.000 description 1
- 241000239311 Buthus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 241001391944 Commicarpus scandens Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241001448862 Croton Species 0.000 description 1
- 230000007018 DNA scission Effects 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000239268 Leiurus quinquestriatus Species 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 102000000424 Matrix Metalloproteinase 2 Human genes 0.000 description 1
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 1
- 101000716700 Mesobuthus martensii Toxin BmKT Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 108091002531 OF-1 protein Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000233091 Rhinoprosopa lucifer Species 0.000 description 1
- 241000273008 Rhopalurus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 102400000827 Saposin-D Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010053649 Vascular rupture Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Substances CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 244000221110 common millet Species 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000009193 crawling Effects 0.000 description 1
- 238000013211 curve analysis Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000001909 effect on DNA Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002919 insect venom Substances 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000001020 neural plate Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000010353 neuronal integration Effects 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000003040 nociceptive effect Effects 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 210000004882 non-tumor cell Anatomy 0.000 description 1
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000008533 pain sensitivity Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000009834 selective interaction Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000007666 subchronic toxicity Effects 0.000 description 1
- 231100000195 subchronic toxicity Toxicity 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 238000002723 toxicity assay Methods 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
- C07K14/43522—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/646—Arachnids, e.g. spiders, scorpions, ticks or mites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Insects & Arthropods (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2010-0186 | 2010-09-27 | ||
| CU2010000186A CU24055B1 (es) | 2010-09-27 | 2010-09-27 | Composiciones farmacéuticas de veneno de escorpión rhopalurus junceus |
| PCT/CU2011/000006 WO2012041261A2 (es) | 2010-09-27 | 2011-09-27 | Peptidos del veneno de escorpion rhopalorus junceus y composicion farmaceutica |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20140041381A true KR20140041381A (ko) | 2014-04-04 |
Family
ID=45566782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020137010868A Ceased KR20140041381A (ko) | 2010-09-27 | 2011-09-27 | 로팔러러스 정셔스 전갈 독으로부터의 펩티드 및 약리학적 조성물 |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP2623111A2 (enExample) |
| JP (1) | JP2013542196A (enExample) |
| KR (1) | KR20140041381A (enExample) |
| CN (1) | CN103200951A (enExample) |
| AP (1) | AP2013006811A0 (enExample) |
| AR (1) | AR083117A1 (enExample) |
| AU (1) | AU2011307691A1 (enExample) |
| BR (1) | BR112013007198A2 (enExample) |
| CA (1) | CA2812841A1 (enExample) |
| CO (1) | CO6781464A2 (enExample) |
| CU (1) | CU24055B1 (enExample) |
| EC (1) | ECSP13012595A (enExample) |
| IL (1) | IL225577A0 (enExample) |
| MX (1) | MX360726B (enExample) |
| RU (1) | RU2563348C2 (enExample) |
| SG (1) | SG191708A1 (enExample) |
| WO (1) | WO2012041261A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103074304B (zh) * | 2013-01-28 | 2016-01-13 | 江苏健安生物科技有限公司 | 高水平人二倍体细胞培养水痘-带状疱疹疫苗病毒方法 |
| MX2019000570A (es) * | 2018-12-19 | 2020-08-13 | Centro De Investig Biologicas Del Noroeste S C | Composición homeopatica a base de veneno de escorpión rhopalurus junceus y su uso en acuicultura. |
| EP4267251A4 (en) * | 2020-12-22 | 2024-12-18 | Preveceutical Medical Inc. | CYCLIC PEPTIDES AND USES THEREOF |
| CN113384682B (zh) * | 2021-05-31 | 2023-07-04 | 南方医科大学 | 蝎毒多肽Smp43在制备抗肿瘤药物的应用 |
| CN117069800B (zh) * | 2023-10-16 | 2023-12-12 | 山东省食品药品检验研究院 | 一种鉴别东亚钳蝎的特征多肽及其应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1030229C (zh) | 1991-12-16 | 1995-11-08 | 山东省蒙阴县酒厂 | 全蝎酒的制作方法 |
| CN1076858A (zh) | 1993-03-24 | 1993-10-06 | 王强华 | 熊胆全蝎酒及其制备工艺 |
| CU22413A1 (es) | 1994-01-11 | 1996-01-31 | Composicion antitumoral | |
| US5905027A (en) | 1995-12-27 | 1999-05-18 | Uab Research Foundation | Method of diagnosing and treating gliomas |
| FR2745004B1 (fr) * | 1996-02-16 | 1998-03-27 | Rhone Poulenc Agrochimie | Peptide antibacterien et antifongique |
| US6168651B1 (en) | 1998-10-08 | 2001-01-02 | Donaldson Company, Inc. | Filter assembly with shaped adsorbent article; and devices and methods of use |
| CN1279088A (zh) | 1999-06-25 | 2001-01-10 | 谷令旗 | 一种治疗肝癌药剂的制备方法 |
| CN1265901A (zh) | 2000-01-26 | 2000-09-13 | 徐忠廷 | 一种抗癌中药丸剂 |
| CN1316249A (zh) | 2001-04-04 | 2001-10-10 | 李滋星 | 全蝎活性营养液 |
| CN1157215C (zh) | 2001-07-30 | 2004-07-14 | 张官锁 | 一种治疗癌症的中药组合物 |
| CN1325514C (zh) * | 2001-09-30 | 2007-07-11 | 沈阳药科大学 | 蝎镇痛抗肿瘤缬精甘肽及获得方法 |
| CN100465272C (zh) * | 2002-01-18 | 2009-03-04 | 中国科学院上海有机化学研究所 | 重组东亚马氏钳蝎毒rBmKaIT1的基因工程 |
| EP2431385A3 (en) * | 2002-05-31 | 2012-07-04 | Morphotek, Inc. | Combination therapy with chlorotoxin |
| CN1256971C (zh) | 2002-08-12 | 2006-05-24 | 徐继康 | 一种用于治疗肿瘤的中药胶囊 |
| US8097284B2 (en) * | 2007-11-13 | 2012-01-17 | Arthur Mikaelian | Polarized scorpion venom solution and a method for making polarized scorpion venom solution |
-
2010
- 2010-09-27 CU CU2010000186A patent/CU24055B1/es not_active IP Right Cessation
-
2011
- 2011-09-27 AR ARP110103520A patent/AR083117A1/es not_active Application Discontinuation
- 2011-09-27 CN CN2011800541685A patent/CN103200951A/zh active Pending
- 2011-09-27 CA CA2812841A patent/CA2812841A1/en not_active Abandoned
- 2011-09-27 JP JP2013530559A patent/JP2013542196A/ja active Pending
- 2011-09-27 BR BR112013007198A patent/BR112013007198A2/pt not_active IP Right Cessation
- 2011-09-27 EP EP11815845.0A patent/EP2623111A2/en not_active Withdrawn
- 2011-09-27 MX MX2013003545A patent/MX360726B/es active IP Right Grant
- 2011-09-27 KR KR1020137010868A patent/KR20140041381A/ko not_active Ceased
- 2011-09-27 SG SG2013022850A patent/SG191708A1/en unknown
- 2011-09-27 AU AU2011307691A patent/AU2011307691A1/en not_active Abandoned
- 2011-09-27 AP AP2013006811A patent/AP2013006811A0/xx unknown
- 2011-09-27 WO PCT/CU2011/000006 patent/WO2012041261A2/es not_active Ceased
- 2011-09-27 RU RU2013119431/10A patent/RU2563348C2/ru active IP Right Revival
-
2013
- 2013-04-04 IL IL225577A patent/IL225577A0/en unknown
- 2013-04-25 CO CO13105491A patent/CO6781464A2/es not_active Application Discontinuation
- 2013-04-29 EC ECSP13012595 patent/ECSP13012595A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011307691A1 (en) | 2013-05-02 |
| MX2013003545A (es) | 2013-11-04 |
| CO6781464A2 (es) | 2013-10-31 |
| BR112013007198A2 (pt) | 2016-06-14 |
| ECSP13012595A (es) | 2014-11-28 |
| WO2012041261A2 (es) | 2012-04-05 |
| CA2812841A1 (en) | 2012-04-05 |
| CU20100186A7 (es) | 2012-06-21 |
| MX360726B (es) | 2018-11-13 |
| SG191708A1 (en) | 2013-08-30 |
| CU24055B1 (es) | 2014-12-26 |
| RU2563348C2 (ru) | 2015-09-20 |
| AR083117A1 (es) | 2013-01-30 |
| WO2012041261A3 (es) | 2012-11-22 |
| CN103200951A (zh) | 2013-07-10 |
| JP2013542196A (ja) | 2013-11-21 |
| IL225577A0 (en) | 2013-06-27 |
| AP2013006811A0 (en) | 2013-04-30 |
| RU2013119431A (ru) | 2014-11-10 |
| EP2623111A2 (en) | 2013-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2473874C (en) | A composition for treating neurocerebrovascular disorders | |
| CN101485655B (zh) | 二氢杨梅素在制备防治肿瘤放化疗不良反应的药物的应用 | |
| KR101285234B1 (ko) | 백미 추출물을 포함하는 관절염 예방 및 치료용 조성물 | |
| KR20140041381A (ko) | 로팔러러스 정셔스 전갈 독으로부터의 펩티드 및 약리학적 조성물 | |
| Shen et al. | Mitochondria-dependent apoptosis of activated T lymphocytes induced by astin C, a plant cyclopeptide, for preventing murine experimental colitis | |
| Gupta et al. | Evaluation of in vitro and invivo anti-inflammatory activities of Parthenium camphora | |
| Ibrahim et al. | Leaves extract of Muntingia calabura protects against gastric ulcer induced by ethanol in Sprague-dawley rats | |
| JP5760145B2 (ja) | 自己免疫障害を治療するための組成物およびその方法 | |
| Park et al. | Polymer fraction of Aloe vera exhibits a protective activity on ethanol-induced gastric lesions | |
| Yu et al. | GB1a ameliorates ulcerative colitis via regulation of the NF-κB and Nrf2 signaling pathways in an experimental model | |
| Qiu et al. | Effect of Cuttlebone on Healing of Indomethacin‐Induced Acute Gastric Mucosal Lesions in Rats | |
| AU2015346430B2 (en) | Apoaequorin-containing compositions and methods of using same to treat neuronal inflammation | |
| KR101028864B1 (ko) | 배무채로부터 설포라펜을 분리하는 방법 및 이의 용도 | |
| CA2954781A1 (en) | Seaweed extract and composition useful against cancer cells | |
| KR101028865B1 (ko) | 무로부터 설포라펜을 분리하는 방법 및 이의 용도 | |
| JP7022064B2 (ja) | 薬用のアンブローシア属植物抽出物 | |
| CN101485791B (zh) | 显齿蛇葡萄总黄酮在制备防治肿瘤放化疗不良反应的药物的应用 | |
| US20250367254A1 (en) | Apoaequorin-Containing Compositions and Method of Using Same to Treat Neuronal Inflammation | |
| CN103694248B (zh) | 从藤黄中提取的抗肿瘤化合物及其制备方法与用途 | |
| Ankalikar et al. | Effect of Hydroalcoholic Extracts of Leaves of Vitex trifolia Linn. on Chronic Inflammation and Tuberculosis. | |
| JP5995235B2 (ja) | シガテラを治療するためのロスマリン酸及びその誘導体の使用 | |
| Akinlolu et al. | ANTI-TOXIC PRINCIPLES FROM MUSA SAPIENTUM AND MORINGA OLEIFERA AMELIORATED SKIN HISTO-PATHOLOGY, DECREASED LIPID PEROXIDATION AND PROMOTED MELATONIN/TNF-ALPHA/P53-MEDIATED APOPTOSIS IN CADMIUM CHLORIDE-INDUCED CARCINOGENESIS IN RATS | |
| Yogamoorthi et al. | Anti-inflammatory and analgesic property of methanolic extract of Spinifex littoreus (Burm. f.) Merr | |
| CN107737333B (zh) | 4-氨基喹啉衍生物与蛇毒细胞毒素-ctx1的药物组合物 | |
| Shawky et al. | Allicin Mitigates Immobilization Stress Induced Gastric Ulcer in Rats by Upregulation of Nrf2/HO-1 Pathway. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20130426 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20160927 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20180405 Patent event code: PE09021S01D |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20181029 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20190719 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20181029 Comment text: Notification of reason for refusal Patent event code: PE06011S01I Patent event date: 20180405 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |